Early attempts to treat HER2-altered NSCLC with pan-HER inhibitors like afatinib, dacomitinib, and neratinib showed limited success, with ORRs ranging between 0–19% and PFS of just 2.8–5.5 month [187,188]. Here, ERBB2 is linked to non-small cell lung carcinoma.